About 39% of surveyed families used cannabis for children with a rare neurodegeneration causing severe dystonia | Research

The takeaway

Among families of children with pantothenate kinase-associated neurodegeneration, 39% reported using cannabis products, typically after many other treatments had failed, with most reporting moderate to significant improvements in dystonia, pain, and sleep.

Parents of children with rare movement disorders, pediatric neurologists, and researchers studying cannabinoids for dystonia and neurodegeneration.

4 of 7 cannabis-using children reported improved dystonia

What the researchers found

7 of 18 respondents (39%) had used cannabis for their child. Cannabis users were on more medications, more likely to have used opiates, and had greater physical impairment. Four children reported moderate or significant improvement in dystonia, 3 in pain, 4 in sleep, 3 in anxiety, and 2 in behavior. Adverse effects were mild (sadness, agitation, tiredness in 1 each).

Why it matters

Children with rare neurodegenerative diseases and severe dystonia often exhaust standard treatments. This survey reveals that families are turning to cannabis and reporting benefits, highlighting the need for controlled studies in pediatric movement disorders.

The numbers in context

18 of 44 families responded. 7 (39%) used cannabis. Mean age 11 years. Cannabis users on median 2 tone medications (range 0-9). Improvements reported: dystonia (4), pain (3), sleep (4), anxiety (3), behavior (2). Adverse effects in 3 children.

How the study worked

Cross-sectional 37-item survey distributed to families of 44 children in a clinical registry of pantothenate kinase-associated neurodegeneration. 18 responses (41% response rate). Cannabis use, sources of information, symptom changes, and adverse effects collected.

What this study cannot tell us

Very small sample (18 respondents, 7 cannabis users). Survey response bias likely favoring families with strong opinions about cannabis. No objective outcome measures. No control group for comparison.

How to read the evidence

Small cross-sectional survey with self-reported outcomes and no controls. Hypothesis-generating but not sufficient to establish efficacy.

When this study was published

2020 survey. One of very few studies examining cannabis use in pantothenate kinase-associated neurodegeneration.

The bigger picture

This study adds to growing evidence that families of children with severe, treatment-resistant neurological conditions are using cannabis, often based on information from other parents rather than medical providers.

Questions still open

Would controlled trials of cannabis in pediatric dystonia show similar benefits? What cannabinoid ratios and doses are optimal for movement disorders? How should physicians counsel families seeking cannabis for treatment-resistant conditions?

Common questions

What is pantothenate kinase-associated neurodegeneration?

PKAN is a rare inherited neurodegenerative disease that causes severe, progressive dystonia (involuntary muscle contractions). It typically begins in childhood and has no curative treatment.

Where did families learn about cannabis for this condition?

The most common source of information was other parents, rather than medical providers, highlighting the informal networks families use when standard treatments are insufficient.

Read the original research

Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration.

Journal of child neurology, 35(4), 259-264

View on PubMed ↗Publisher’s paper ↗

Citation

Wilson, Jenny L; Gregory, Allison; Wakeman, Katrina; Freed, Alison; Rai, Puneet; Roberts, Colin; Hayflick, Susan J; Hogarth, Pennylope. (2020). Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration.. Journal of child neurology, 35(4), 259-264. https://doi.org/10.1177/0883073819890516